Table 3.

The effect of RDN on mRNA expression of pro-atherosclerosis markers, angiotensin receptors, and α2 adrenergic receptors.

	Sham	RDN
AT1A	0.801 (0.735–1.364)	0.984 (0.574–1.295)
AT1B	0.834 (0.004–1.996)	0.039 (0.005–0.534)
AT2	0.803 (0.657–1.442)	1.669 (0.559–2.252)
Adra2	1.076 (0.784–1.178)	0.951 (0.546–1.293)
IL-6	1.011 (0.713–1.282)	0.501 (0.312–1.402)
iNOS	1.022 (0.741–1.0248)	1.311 (0.429–1.872)
MCP-1	0.633 (0.431–1.713)	0.433 (0.300–0.587)
NF-κB	0.951 (0.724–1.300)	0.890 (0.628–1.369)
MMP-9	0.969 (0.778–1.238)	1.472 (0.761–2.281)
TNF-α	0.863 (0.709–1.359)	0.992 (0.613–1.273)

Mice were euthanized after infusion with angiotensin II for 28 days, and the thoracic aortic was used for RNA extraction. mRNA expression was analyzed using quantitative PCR. The relative gene expression was normalized using EEF2 as a reference gene. Data were expressed as median and interquartile range. N = 5 for sham surgery, and N = 6 for RDN. P > 0.05 for all the genes tested in the table. Adra2, alpha-2 adrenergic receptor; AT1A, type 1A angiotensin receptor; AT1B, type 1B angiotensin receptor; AT2, type 2 angiotensin receptor; IL, interleukin; iNOS, inducible nitric oxide synthase; MCP-1, monocyte chemoattractant protein-1; MMP, matrix metalloproteinase; NF-κB, nuclear factor-kappa B; RDN, renal denervation; TNF-α, tumor necrosis factor-alpha.